In this single-center study of 120 AIS patients treated with i.v. t-PA, we show for the first time that results of the thrombin generation test obtained before the thrombolytic treatment could be a useful marker to predict short- and long-term outcomes. The gene discussed is PLAT; the disease is androgen insensitivity syndrome.